IP Library › Granted Patent US 12662511
Granted Patent B2
US 12662511 · App. 17/912,482 · Granted Jun 23, 2026

Molecular transport system to the central nervous system

Inventors: Kathlynn C. Brown (Menlo Park, CA); Michael McGuire (Menlo Park, CA); Indu Venugopal (Menlo Park, CA)
Assignee: SRI International
C07K7/08A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662511
App. No.
17/912,482
Granted
Jun 23, 2026
Kind
B2
Abstract

Disclosed herein are MTS peptides or targeting peptides. Disclosed are MTS peptides comprising the amino acid sequence of any one of SEQ ID NOs: 1-12. Disclosed are compositions comprising a peptide, wherein the peptide comprises a first MTS peptide conjugated to a cargo. Also disclosed are methods of using the MTS peptides. For example, disclosed are methods of transporting cargo to the CNS comprising administering one or more of the disclosed compositions to a subject in need thereof, wherein the peptide conjugated to cargo enters the CNS.

Claims (22)

1 . A molecular transport system (MTS) peptide for use in targeting the central nervous system (CNS), the MTS peptide comprising the amino acid sequence of:

NQEYQHHKIKVRPSHQ (SEQ ID NO:3),

FPSWTSKNQQWTNQRQ (SEQ ID NO:4),

AHMSQKRLPHQVHQHQ (SEQ ID NO:5),

AGNKYEYTMHQKHNK (SEQ ID NO:6),

SKETYSMNAQRQHERS (SEQ ID NO:7),

HRYDADRHHSFTPQYH (SEQ ID NO:8),

NEEMHQAQRHHVQW (SEQ ID NO:9), or

ALEPWGYKQVIKMAPN (SEQ ID NO:10).

2 . The MTS peptide of claim 1 , wherein the MTS peptide has an N-terminal protection group.

3 . The MTS peptide of claim 1 , wherein the MTS peptide further comprises a linker.

4 . The MTS peptide of claim 3 , wherein the linker comprises polyethylene glycol (PEG).

5 . The MTS peptide of claim 1 , wherein the MTS peptide is covalently conjugated to a cargo, directly or through a linker.

6 . The MTS peptide of claim 5 , wherein the cargo is a protein, peptide, nucleic acid, antibody, a chemical compound, or a small molecule.

7 . The MTS peptide of claim 6 , wherein the compound is an imaging agent.

8 . The MTS peptide of claim 6 , wherein the cargo is a therapeutic.

9 . The MTS peptide of claim 5 , wherein the MTS peptide further comprises a second MTS peptide, which may be different or the same as the MTS peptide.

10 . A composition comprising a MTS peptide of claim 5 , wherein the MTS peptide is configured to transport the cargo to the CNS via the cerebral spinal fluid (CSF).

11 . The composition of claim 10 , wherein the cargo is a protein, peptide, nucleic acid, antibody, a chemical compound, or a small molecule.

12 . The composition of claim 11 , wherein the compound is an imaging agent.

13 . The composition of claim 10 , wherein the cargo is a therapeutic.

14 . The composition of claim 10 , wherein the linker comprises polyethylene glycol (PEG).